Targeted Treatment of Papillary Craniopharyngiomas Harboring BRAF V600E Mutations

Cancer - United States
doi 10.1002/cncr.32197
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Redifferentiation of Iodine-Refractory BRAF V600e-Mutant Metastatic Papillary Thyroid Cancer With Dabrafenib

Clinical Cancer Research
Cancer ResearchOncology
2014English

Newly Diagnosed Papillary Craniopharyngioma With BRAF V600E Mutation Treated With Single-Agent Selective BRAF Inhibitor Dabrafenib: A Case Report

Oncotarget
Oncology
2019English

The BRAF V600E Mutation Is a Predictor of the Effect of Radioiodine Therapy in Papillary Thyroid Cancer

Journal of Cancer
Oncology
2020English

The Significance of TROP2 Expression in Predicting BRAF Mutations in Papillary Thyroid Carcinoma

Journal of Pathology and Translational Medicine
Forensic MedicinePathologyHistology
2018English

Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma

Clinical Cancer Research
Cancer ResearchOncology
2019English

Distinct BRAF (V600E) and KRAS Mutations in High Microsatellite Instability Sporadic Colorectal Cancer in African Americans

Clinical Cancer Research
Cancer ResearchOncology
2009English

Surgical Tactics Optimization for Treatment of BRAF Positive Papillary Thyroid Cancer

Clinical and experimental thyroidology
2018English

OA12.06 Mutational Landscape of BRAF V600E Positive Lung Cancer Patients Following BRAF Directed Therapy Failure

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Tall Cell Papillary Thyroid Carcinoma: New Diagnostic Criteria and Mutations in BRAF and TERT

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy